^
    1d
    Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Jan 2027 --> Dec 2025
    Trial primary completion date
    |
    Mektovi (binimetinib) • Beleodaq (belinostat)
    1d
    the HOPE trial: Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=34, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Dec 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mektovi (binimetinib) • hydroxychloroquine
    1d
    Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Emory University | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Mar 2029
    Trial completion date • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS G12C • KRAS G12
    |
    Opdivo (nivolumab) • Avmapki (avutometinib) • Fakzynja (defactinib) • ABP 206 (nivolumab biosimilar)
    3d
    Comparative efficacy and safety of nivolumab-based combination therapies (with ipilimumab or binimetinib) in patients with microsatellite-stable and microsatellite-instability-high metastatic colorectal cancer: a systematic review and meta-analysis. (PubMed, Clin Transl Oncol)
    In metastatic CRC patients who receive nivolumab-based combination therapies demonstrate partial tumor responses that increase while their safety profile remains acceptable, but their overall response rates do not improve. The research demonstrates how immunotherapy serves as a standard treatment method for MSI-H disease while emphasizing the need to develop biomarker-driven approaches that enhance treatment selection methods, especially for MSS CRC.
    Retrospective data • Review • Journal • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • MSI-H
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Mektovi (binimetinib)
    4d
    A novel AGTPBP1-ERK/MYLK network mediates pancreatic cancer progression. (PubMed, Tissue Cell)
    Mechanistically, AGTPBP1 activated the MAPK/ERK pathway through elevated ERK1/2 phosphorylation, and pharmacological inhibition of ERK phosphorylation using PD98059 abrogated both ERK phosphorylation and AGTPBP1-driven phenotypes, establishing ERK as an essential mediator...Notably, ERK signaling modulated MYLK activity (phosphorylated MYLK) without altering MYLK expression, indicating that AGTPBP1 regulates MYLK at the transcriptional level, whereas ERK controls its post-translational activity. Collectively, AGTPBP1 promotes PDAC progression through a dual mechanism involving ERK-dependent proliferative signaling and ERK-independent MYLK upregulation, positioning both molecules as potential therapeutic targets.
    Journal
    |
    GBP1 (Guanylate Binding Protein 1) • MYLK (Myosin Light Chain Kinase)
    |
    PD98059
    5d
    Mirdametinib and abemaciclib cooperate in atypical teratoid rhabdoid tumor to decrease proliferation and suppress tumor growth. (PubMed, bioRxiv)
    Mirdametinib and abemaciclib combined to extend survival of mice bearing orthotopic ATRT xenografts. In conclusion, mirdametinib has single agent activity against ATRT and combines with abemaciclib to decrease proliferation and extend survival in orthotopic xenograft models of ATRT.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    Verzenio (abemaciclib) • Gomekli (mirdametinib)
    5d
    DTP-HER2: A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Kolupin (tunlametinib)
    5d
    EAY191-A6: Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Oct 2026 | Trial primary completion date: May 2026 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    MAPK1 (Mitogen-activated protein kinase 1)
    |
    BRAF V600E • BRAF V600
    |
    Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical
    5d
    Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Koselugo (selumetinib) • Recentin (cediranib)
    6d
    Dabrafenib and/or Trametinib Rollover Study (clinicaltrials.gov)
    P4, N=100, Recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2030 --> Dec 2032 | Trial primary completion date: Dec 2029 --> Dec 2032
    Trial completion date • Trial primary completion date
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    6d
    MEK-NF1-105: To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants (clinicaltrials.gov)
    P1, N=36, Completed, SpringWorks Therapeutics, Inc. | Not yet recruiting --> Completed | Trial completion date: Oct 2026 --> Feb 2026
    Trial completion • Trial completion date
    |
    Gomekli (mirdametinib)